報價延遲最少15分鐘:2026/04/17 17:21 EDT
盤後時段
|
||||
|
10.67 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.67
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.35/1.33
|
|
企業價值
673.39M
|
| 資產負債 |
|
每股賬面淨值
2.63
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
106.47M
|
|
每股收益
0.28
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market. |
